AR and prostate cancer: We have previously reported that the compound A4B17 derived from a screen of 47 benzothiazoles inhibited proliferation of ER+ breast and AR+ prostate cancer cells with half maximal inhibitory concentrations (IC50) in the micromolar range (19, 20).